Canonica Giorgio Walter, Passalacqua Giovanni, Incorvaia Cristoforo, Cadario Gianni, Fiocchi Alessandro, Senna Gianenrico, Rossi Oliviero, Romano Antonino, Scala Enrico, Romano Catello, Ingrassia Antonino, Zambito Marcello, Dell'Albani Ilaria, Frati Franco
Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Allergy Asthma Proc. 2014 Jan-Feb;35(1):43-6. doi: 10.2500/aap.2013.34.3721.
The efficacy of allergen immunotherapy (AIT) is well supported by evidence from trials and meta-analyses. However, its actual performance in daily practice may be diminished by several pitfalls, including inappropriate patient selection, and, especially, the use of allergen extracts of insufficient quality. We performed a survey, the Allergen Immunotherapy Decision Analysis, to evaluate which criteria specialists use to choose products for sublingual immunotherapy (SLIT) in adult patients suffering from allergic respiratory disease. We surveyed a total of 169 Italian allergists randomly chosen from a database belonging to a market research company (Lexis Ricerche, Milan, Italy). The survey was performed between October and November 2012 under the aegis of the European Center for Allergy Research Foundation and consisted of a questionnaire-based electronic survey prepared by a scientific board of 12 AIT experts. The questionnaire comprised two parts, the first of which contained 14 items to be ranked by each participant according to the importance assigned to each when choosing SLIT products. The physicians' rankings assigned major importance to the level of evidence-based validation of efficacy and safety, standardization of the product, efficacy based on personal experience, and defined content(s) of the major allergen(s) in micrograms. The results of this survey show that Italian allergists rank the quality-related characteristics of allergen extracts as highly important when choosing products for AIT. The allergists' preference for high-quality products should be addressed by regulatory agencies and by producers.
变应原免疫疗法(AIT)的疗效得到了试验和荟萃分析证据的充分支持。然而,其在日常实践中的实际效果可能会因一些缺陷而降低,包括患者选择不当,尤其是使用质量不佳的变应原提取物。我们开展了一项名为“变应原免疫疗法决策分析”的调查,以评估专家在为患有过敏性呼吸道疾病的成年患者选择舌下免疫疗法(SLIT)产品时所采用的标准。我们从一家市场研究公司(意大利米兰的Lexis Ricerche)的数据库中随机挑选了169名意大利过敏症专科医生进行调查。该调查于2012年10月至11月在欧洲过敏研究基金会的支持下进行,由一个由12名AIT专家组成的科学委员会编制的基于问卷的电子调查组成。问卷包括两部分,第一部分包含14个项目,每位参与者需根据在选择SLIT产品时对每个项目的重视程度进行排序。医生们的排序将疗效和安全性的循证验证水平、产品的标准化、基于个人经验的疗效以及主要变应原以微克计的规定含量视为重要因素。本次调查结果表明,意大利过敏症专科医生在为AIT选择产品时,将变应原提取物与质量相关的特征视为非常重要。监管机构和生产商应关注过敏症专科医生对高质量产品的偏好。